Open-Label Extension to Evaluate the Longer Term Efficacy and Safety of LIB003

NCT03847974 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

32

Enrollment

INDUSTRY

Sponsor class

Conditions

Hypercholesterolemia

Interventions

DRUG: LIB003

Sponsor

LIB Therapeutics LLC